Meloxicam in Mohs Micrographic Surgery

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

June 2, 2026

Study Completion Date

August 2, 2026

Conditions
Postoperative Pain, AcuteSkin Cancer
Interventions
DRUG

Meloxicam 7.5 mg

This intervention is the mandatory oral Meloxicam 7.5mg dose after Mohs closure.

DRUG

Meloxicam 15 mg

This intervention is the mandatory oral Meloxicam 15mg dose after Mohs closure.

DRUG

Acetaminophen 500mg

This randomized control group will take a mandatory one-time dose of 500 mg acetaminophen with alternating 200 mg ibuprofen and 500 mg acetaminophen (standard of care) every 3 hours for pain.

Trial Locations (1)

73104

University of Oklahoma Health Sciences Center, Oklahoma City

All Listed Sponsors
lead

University of Oklahoma

OTHER